Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays
Open accessThe DOI matches its Crossref record; 309 of the 334 references it cites were found in a registry or an index; 163 of the 299 sources its claims cite were checked for support.
Abstract
Inherited retinal dystrophies and optic neuropathies cause chronic disabling loss of visual function. The development of recombinant adeno-associated viral vectors (rAAV) gene therapies in all disease fields have been promising, but the translation to the clinic has been slow. The safety and efficacy profiles of rAAV are linked to the dose of applied vectors. DNA changes in the rAAV gene cassette affect potency, the expression pattern (cell-specificity), and the production yield. Here, we present a library of rAAV vectors and elements that provide a workflow to design novel vectors. We first performed a meta-analysis on recombinant rAAV elements in clinical trials (2007–2020) for ocular gene therapies. We analyzed 33 unique rAAV gene cassettes used in 57 ocular clinical trials. The rAAV gene therapy vectors used six unique capsid variants, 16 different promoters, and six unique polyadenylation sequences. Further, we compiled a list of promoters, enhancers, and other sequences used in current rAAV gene cassettes in preclinical studies. Then, we give an update on pro-viral plasmid backbones used to produce the gene therapy vectors, inverted terminal repeats, production yield, and rAAV safety considerations. Finally, we assess rAAV transgene and bioactivity assays applied to cells or organoids in vitro, explants ex vivo, and clinical studies.
Overview
CoChat Summary
TL;DR
This review/meta-analysis catalogs recombinant AAV vector elements used in ocular gene therapy clinical trials (2007–2020) and preclinical assays, analyzing 33 unique rAAV gene cassettes from 57 trials. It provides a workflow/library of capsids, promoters, enhancers, introns, polyadenylation sequences, production considerations, and transgene/bioactivity assay models for designing ocular rAAV vectors.
Key findings
- The meta-analysis identified 33 unique rAAV gene cassettes used in 57 ocular clinical trials; these used six unique capsid variants, 16 different promoters, and six unique polyadenylation sequences.
- Five different AAV-RPE65 products were tested in 13 clinical trials, leading to the first retinal gene therapy approved by the FDA in December 2017 and EMA in November 2018 (AAV-hRPE65v2; voretigene neparvovec-rzyl, LUXTURNA).
- The review compiles vector elements including capsids, ubiquitous and cell-specific promoters, enhancers, introns, WPRE, polyadenylation sequences, pro-viral plasmid backbones, ITRs, and production platforms; it notes rAAV packaging capacity of about 4.5–4.6 kb excluding ITRs, while scAAV reduces capacity to a maximum of 2.5 kb including ITRs.
- Assay models reviewed include in vitro cell lines, hiPSC-derived RPE, retinal organoids, ex vivo human retina, and in vivo/NHP studies; NHP and human retinal explants matched more closely (correlation r = 0.66–0.67) than mouse/human comparisons (r = 0.24–0.32).
Methods
- Meta-analysis: clinical trial identifiers were collected from reviews on ocular gene therapy, then searched on clinicaltrials.gov using keywords including AAV, gene therapy, retinitis pigmentosa, RP, Leber congenital amaurosis, LCA, AMD, and CHM, with last search date 01 April 2020; the search was limited to ocular gene therapies and cross-checked against news, reviews, Ph.D. theses, patents, SEC filings, company websites, presentations, and conference abstracts.
- The 33 unique rAAV ocular gene therapy products were analyzed for prokaryotic plasmid backbone, ITR AAV serotype, enhancers, promoters, introns, cDNA genes, codon optimization, human or other species-related sequences, post-transcriptional stabilizing sequences, polyadenylation sequences, and rAAV production platform; missing information was indicated as “UntoldR” or “?”.
- The paper also compiles preclinical promoters, enhancers, and other sequences and reviews transgene expression assays and biological activity assays across in vitro, ex vivo, and in vivo models.
Limitations
- The paper states that many papers on rAAV ocular trials do not sufficiently describe the elements on the plasmid used for viral vector production, including bacterial origin and bacterial selection markers, and that poor description and the vast expanse of rAAV vectors make fair comparison of vector elements very challenging.
- The paper states that large-scale comparative rAAV element studies are missing in ophthalmology; it also notes that rAAV integration studies in the retina are underrepresented and that almost no rAAV study specifically investigated rAAV integration events.
- Evident from the text: as a review/meta-analysis, it does not report new primary experimental data, and missing or incomplete source information is marked as “UntoldR” or “?”, indicating reliance on secondary and sometimes incomplete public/company documentation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4 How to assess Inverted Terminal Repeats (ITRs) of rAAV and how they allow concatemerization. (A) Restriction enzyme sites in the AAV serotype 2 ITR in the flop configuration. RBE’/RBE binds Rep68 (RBE, Rep-binding element) and initiates the Rep helicase. The Rep helicase nicks the trs (terminal resolution site). Restriction enzyme recognition site indicated in blue and the actual cut in red. Figure adapted from [238]. (B) ITR structure in the nucleus after second-strand DNA synthesis in dividing cells favoring homologous recombination. Most rAAV-vectors form episomal concatemeric circular double-stranded DNA.](https://figures.cochat.ai/paper-figures/d2cf029bfc5c418988eb657099b1a410/recombinant-adeno-associated-viral-vectors-raav-vector-elements-in-ocular-gene-figure-4.jpg)
![Figure 5 A hypothetical model of the spread of rAAV capsids (serotypes 1, 2, 5 8, and 9) after intravitreal or subretinal injection in disease or non-disease mouse retinas in vivo based on the studies [99,294,304,306,308,309]. RPE, retinal pigment epithelium; OLM, outer limiting membrane, ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; GCL, ganglion cell layer; ILM, Inner Limiting Membrane.](https://figures.cochat.ai/paper-figures/e3f5847ede504cb38d2d032ab640db72/recombinant-adeno-associated-viral-vectors-raav-vector-elements-in-ocular-gene-figure-5.jpg)

Verification
Claims the paper makes
109 Valid · 57 Not valid · 98 Not checked · 102 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Relative tissue-specific expression of two gRNAs for CRISPR/Cas gene editing in myotubes was achieved by linking a muscle-specific MHCK7 promoter (pol II) with gRNA-linked self-cleaving ribozyme sequences derived of Hepatitis delta virus (HDV) and a Hammerhead (HH) sequence [134-137].”
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > 3.5. Small Nuclear RNA (snRNA) Promoters
What the sources say
- Partly supportedcites [134] Eckenfelder, 2012, The Cellular Processing Capacity Limits the Amounts of Chimeric U7 snRNA Available for Antisense Delivery, Mol. Ther. Nucleic Acids sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [135] Salva, 2007, Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle, Mol. Ther. source
- Disputedcites [136] LaVail, 2000, Ribozyme rescue of photoreceptor cells in P23H transgenic rats: Long-term survival and late-stage therapy, Proc. Natl. Acad. Sci. USA sourceExperimental — accuracy not yet measured
The Abstract (page unavailable) describes a different construct: rAAV vectors used a proximal bovine rod opsin promoter to express hairpin or hammerhead ribozymes in rat photoreceptors. Those ribozymes targeted mutant rhodopsin transcripts; the paper does not describe MHCK7-driven, HDV/hammerhead-flanked CRISPR gRNAs in myotubes. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Supportedcites [137] Xu, L., Zhao, L., Gao, Y., Xu, J., and Han, R. (2017). Empower multiplex cell and tissue-specific CRISPR-mediated gene manipulation with self-cleaving ribozymes and tRNA. Nucleic Acids Res., 45. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“However, if left active in cells, functional rAAV-CRISPR/Cas9 systems do increase the number of off-target integration events into the genome [218].”
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > 4.3. rAAV-Vectors Expressing CRISPR/Cas
What the sources say
- Disputedcites [218] Hanlon, K.S., Kleinstiver, B.P., Garcia, S.P., Zaborowski, M.P., Volak, A., Spirig, S.E., Muller, A., Sousa, A.A., Tsai, S.Q., and Bengtsson, N.E. (2019). High levels of AAV vector integration into CRISPR-induced DNA breaks. Nat. Commun., 10. sourceExperimental — accuracy not yet measured
The Results (Genome-wide AAV mapping from mouse brain) report no increase in the overall number of integration sites when Cas9 and gRNA were both present, and say integration at predicted off-target cut sites was below detection. The Discussion likewise reports no significant increase in overall AAV integration with Cas9; the increase was at CRISPR target sites, not off-target sites. The paper raises sustained nuclease activity as a potential concern but does not report the claimed off-target increase. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Because of the relatively large size of 4277 bp of dCas9-VPR cDNA, the authors used a dual rAAV system to express the dCas9-VPR and gRNA expression cassettes [223,224].”
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > 4.3. rAAV-Vectors Expressing CRISPR/Cas
What the sources say
- Disputedcites [223] Kocak, 2013, RNA-guided gene activation by CRISPR-Cas9-based transcription factors, Nat. Methods sourceExperimental — accuracy not yet measured
The paper’s Online Methods (Plasmids; Cell culture and transfection, page unavailable) describe a dCas9-VP64 construct and transfection of plasmids encoding dCas9-VP64 and gRNAs, not a dual rAAV system expressing dCas9-VPR. Our copy does not give a 4277-bp dCas9-VPR cDNA size or attribute the delivery method to that size. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Disputedcites [224] Konermann, 2015, Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex, Nature sourceExperimental — accuracy not yet measured
The Extended Data Figure 7 caption describes three lentiviral vectors expressing sgRNA, dCas9-VP64, and MS2-p65-HSF1, not a dual rAAV system expressing dCas9-VPR and gRNA. The genome-scale gene activation screen section likewise identifies the delivery system as lentiviral. These passages do not give a 4277-bp dCas9-VPR cDNA size. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The hypoxia-induced Müller glial specific promoter showed no luciferase expression in HEK293, C6, HT22, and ARPE19 cells [97].”
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > 5.1. In Vitro Immortalized Epithelial Cell Lines for Transgene and Bioactivity Assays
What the sources say
- Disputedcites [97] Prentice, 2011, Hypoxia-regulated retinal glial cell-specific promoter for potential gene therapy in disease, Investig. Ophthalmol. Vis. Sci. sourceExperimental — accuracy not yet measured
The Figure 4 caption says the regulated promoter had basal or minimal expression in HEK, C6, HT22, and ARPE-19 cells, not no expression. The Hypoxic Induction and Cell Specificity section reports no hypoxic induction in those lines; that does not establish an absence of luciferase expression. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The ubiquitous UbC promoter showed no toxicity to the mouse RPE [324].”
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > 5.6.4. Cis-Regulatory Toxicity of rAAV Vectors In Vivo?
What the sources say
- Disputedcites [324] Xiong, 2019, AAV cis-regulatory sequences are correlated with ocular toxicity, Proc. Natl. Acad. Sci. USA sourceExperimental — accuracy not yet measured
The Results section on RPE toxicity says the broadly active UbiC promoter induced strong RPE toxicity, the opposite of the claim. The study used subretinal AAV injections in mice, as described in the Results section on photoreceptor toxicity. (LLM, conf=0.95)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
203 more claims · 84 with their cited sources checked
Create a free account to see all 366 claims and to verify the 4 references still open.
- It may state two separate claims as one. 107
- Probably not a substantial claim. 78
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The immune reactions include induction of neutralizing antibodies that reduce the number of capsids reaching the target cells, innate immune pathways silencing the gene cassette within the host cell, and cell-mediated T-cell immune responses against foreign protein expression.”
From Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses (2022) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unlike adenoviruses, AAVs generate relatively mild innate and adaptive immune responses, which allow for stable long-term transgene expression.”
From Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses (2022) · cites this paper as [18]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Since then, AAV-mediated gene delivery into the retina has been used in several proof-of-concept studies to target photoreceptors or the RPE in mice and larger models (such as dogs) [63,64,65].”
From The Ocular Gene Delivery Landscape (2021) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > 2. Ocular rAAV Vector-Based Therapies in Clinical Trials
“a promoter shortened to 750 bp (NA65p)”
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > 7.1. A Meta-Analysis on Pro-Viral Plasmids and Production Platforms for Ocular rAAV Therapies in Clinical Trials
“| NA65p | 1383 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > Additional information
“Lentiviral products, cell therapy products, antibodies, and antisense oligonucleotide (AONs) products were removed from Figure 3 and Table 1 to include only rAAV-based therapies.”
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > 7.1. A Meta-Analysis on Pro-Viral Plasmids and Production Platforms for Ocular rAAV Therapies in Clinical Trials
“| Usher | | UshStat | EIAV | CMV | | WPRE | MYO7A | SIN-LTR | HEK293 | | Usher | | QR-421a | | | | AON-USH2A | | | Synthetic |”
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Sun, 2010, Gene therapy with a promoter targeting both rods and cones rescues retinal degeneration caused by AIPL1 mutations, Gene Ther., 17, 117, 10.1038/gt.2009.104”
Cited work 10.1038/gt.2009.104 · retracted 2024-11-15 · notice 10.1038/s41434-024-00505-6 · this paper published 2020-06-12
Citations
Cites
1 retracted
Sun, X., Pawlyk, B., Xu, X., Liu, X., Bulgakov, O. V., Adamian, M., Sandberg, M. A., Khani, S. C., Tan, M.-H., Smith, A. J., et al. (2010) · Gene Therapy · doi:10.1038/gt.2009.104 · Cited by 123
RetractedEfficient selection for high-expression transfectants with a novel eukaryotic vector
Hitoshi, N., Ken-ichi, Y., & Jun-ichi, M. (1991) · Gene · doi:10.1016/0378-1119(91)90434-d · Cited by 5,134
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
Konermann, S., Brigham, M. D., Trevino, A. E., Joung, J., Abudayyeh, O. O., Barcena, C., Hsu, P. D., Habib, N., Gootenberg, J. S., Nishimasu, H., et al. (2015) · Nature · doi:10.1038/nature14136 · Cited by 2,825 · cited 1×
“Because of the relatively large size of 4277 bp of dCas9-VPR cDNA, the authors used a dual rAAV system to express the dCas9-VPR and gRNA expression cassettes [223,224].”
BackgroundAdeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 1×
“Dose finding studies have shown that a high number of rAAV particles (>1012 viral genomes (vg)) can give rise to transient inflammation in mice [35].”
BackgroundSTEROID RECEPTOR REGULATED TRANSCRIPTION OF SPECIFIC GENES AND GENE NETWORKS
Yamamoto, K. R. (1985) · Annual Review of Genetics · doi:10.1146/annurev.ge.19.120185.001233 · Cited by 1,872 · cited 1×
“Active when glucocorticoids or progestins present [175,176]”
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006) · Nature · doi:10.1038/nature04791 · Cited by 1,677 · cited 1×
“Cellular toxicity can, for example, be observed in rAAV shRNA overexpression studies in which ubiquitous promoters were used that caused saturation of cellular miRNA pathways [88].”
BackgroundDynan, W. S., & Tjian, R. (1983) · Cell · doi:10.1016/0092-8674(83)90210-6 · Cited by 1,445 · cited 1×
“For example, the transactional activation of the widely used CMV or early SV40 promoters is related to the binding of the ubiquitous transcription factors Sp1/Sp3 [92,93].”
MethodPurification and biochemical characterization of the promoter-specific transcription factor, Sp1
Briggs, M. R., Kadonaga, J. T., Bell, S. P., & Tjian, R. (1986) · Science · doi:10.1126/science.3529394 · Cited by 1,435 · cited 1×
“Moreover, most mammalian cells express the Sp1 transcription factor [94].”
BackgroundConvection-enhanced delivery of macromolecules in the brain.
Bobo, R. H., Laske, D. W., Akbasak, A., Morrison, P. F., Dedrick, R. L., & Oldfield, E. H. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.6.2076 · Cited by 1,415 · cited 1×
“MVM Ubiquitous, ++ [54,67] MeCP2 229 ubiquitous [68] CMV 800 Ubiquitous, ++, prone to silencing [54] shCMV 220 Ubiquitous, ++ [24]”
Research works printed but not linked: 5
- Fahim, A.T., Daiger, S.P., and Weleber, R.G. (2017, January 19). Nonsyndromic Retinitis Pigmentosa Overview, Available online: http://www.ncbi.nlm.nih.gov/pubmed/20301590.
- Kremer, J.M.J., Keunen, J.E.E., and van Wijk, H.A.R. (2018). Gene therapy using miniUSH2A genes improves visual function in a zebrafish ush2a knock-out model. Towards gene therapy for USH2A-associated retinitis pigmentosa. ~Fishing for answers~ [Doctoral Thesis], Radboud University Nijmegen.
- 2017, The pathway from genes to gene therapy in glaucoma: A review of possibilities for using genes as glaucoma drugs, Asia-Pacific J. Ophthalmol., 6, 80
- Ceiler, J., Afzal, S., Leuchs, B., Fronza, R., Lulay, C., Büning, H., Schmidt, M., and Gil-Farina, I. (2017, January 10). Wild-Type and Recombinant AAV Integration in Human Cardiomyocytes: Focus on Mitochondrial Genome. Proceedings of the AAV Vector Biology, Available online: https://www.researchgate.net/publication/316699961_Wild-Type_and_Recombinant_AAV_Integration_in_Human_Cardiomyocytes_Focus_on_Mitochondrial_Genome.
- Couto, 2016, Poster C0048 ARVO: Potency Assay for AAV Vector Encoding Retinal Pigment Epithelial 65 Protein, Investig. Ophthalmol. Vis. Sci., 57, 1
Cited by
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
“116 Another study reported that a fragment of the mouse methyl-CpG-binding protein-2 promoter enabled robust long-term expression speci fi cally in neurons.”
BackgroundGene therapy advances: A meta-analysis of AAV usage in clinical settings
Au, H. K. E., Isalan, M., & Mielcarek, M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.809118 · Cited by 284
“Selecting the right capsid and promoter is the first step to improve targeted cell transduction and expression (2, 15).”
BackgroundAAV vector development, back to the future
Suárez-Amarán, L., Song, L., Tretiakova, A. P., Mikhail, S., & Samulski, R. J. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.064 · Cited by 101
Nieuwenhuis, B., Laperrousaz, E., Tribble, J. R., Verhaagen, J., Fawcett, J. W., Martin, K. R. G., Williams, P. A., & Osborne, A. (2023) · Gene Therapy · doi:10.1038/s41434-022-00380-z · Cited by 88
Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses
Ghoraba, H. H., Akhavanrezayat, A., Karaca, I., Yavari, N., Lajevardi, S., Hwang, J., Regenold, J., Matsumiya, W., Pham, B., Zaidi, M., et al. (2022) · Clinical Ophthalmology · doi:10.2147/opth.s364200 · Cited by 76
“The immune reactions include induction of neutralizing antibodies that reduce the number of capsids reaching the target cells, innate immune pathways silencing the gene cassette within the host cell, and cell-mediated T-cell immune responses against foreign protein expression.(18)”
Background
Metadata
- Authors
- Buck, T., & Wijnholds, J.
- Affiliations
- Leiden University Medical Center (NL)
- Netherlands Institute for Neuroscience (NL)
- Corresponding author
- Wijnholds, Jan
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-06-12
- Volume
- 21
- Issue
- 12
- Pages
- 4197
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7352801
- OpenAlex
- W3035416273
- Cited by
- 92
- References
- 334
- Citations by year
- 2026: 10 · 2025: 17 · 2024: 17 · 2023: 15 · 2022: 16 · 2021: 15 · 2020: 2
- FWCI
- 1.71
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- KNAW Research Portal (The Royal Netherlands Academy of Arts and Sciences) (publishedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- KNAW research portal (Royal Academy of Art and Sciences (KNAW)) (submittedVersion, other-oa)
- Funders
- Foundation Fighting Blindness (TA-GT-0715-0665-LUMC)
- The Netherlands Organization for Health Research and Development (43200004)
- Million Dollar Bike Ride Grant Program (MDBR-19-131-CRB1, MDBR-20-112-CRB1)
- Dutch blindness funds (Uitzicht 2013-13)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus vectors, ocular gene therapy, inherited retinal disease, optic neuropathy, promoter, inverted terminal repeats, biological activity assay, retinal organoids, clinical trials
- MeSH terms
- Dependovirus, Clinical Trials as Topic, Genetic Vectors, Optic Nerve Diseases, Promoter Regions, Genetic, Genetic Therapy, Treatment Outcome, Polyadenylation, Capsid Proteins, Retinal Dystrophies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-01, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-01 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays. https://app.cochat.ai/papers/10.3390/ijms21124197
- The paper
- Buck, T., & Wijnholds, J. (2020). Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms21124197
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.